Question to the Department for Education:

To ask the Secretary of State for Education, what assessment she has made of the potential impact of the rise in young people not in education, employment or training on local economic growth in Leicester; and what funding is being allocated to local authorities in the East Midlands to tackle this trend.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The government recognises that supporting young people into education, training and employment is key to economic growth and improving living standards. In 2026, 6.9% of 16 to 17-year-olds in Leicester were not in education, employment or training (NEET) or their activity was not known, unchanged from 2025. This was above the East Midlands rate of 6.2% and the England rate of 5.8%.

The government is investing an additional £2.5 billion over three years through the Youth Guarantee and Growth and Skills Levy, alongside measures to prevent young people from becoming NEET.

The East Midlands received £5 million as one of eight Youth Guarantee Trailblazers testing joined-up local approaches. In Leicester, the city council provides targeted prevention and re-engagement support through its Connexions service and is participating in the Adult Skills Fund Pathways to Devolution pilot. This will help strengthen local approaches to supporting young people into education, employment and training. Locally, Leicester College’s Launchpad programme supports young people furthest from the labour market.

Question to the Department for Education:

To ask the Secretary of State for Education, what estimate her department has made of annual taxpayer write-offs resulting from unrecovered student loan debt issued to non-UK citizens.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The total amount written off from unrecovered student loan debt issued to borrowers who were non-UK nationals in the 2025/26 financial year was £29 million, to the nearest million, of which 82% was written off due to death of the borrower or the borrower reaching 65 years of age.

An additional £40 million was written off in loans to borrowers of unknown nationality, which could be UK or non-UK nationals. The nationality of all borrowers is checked and validated during the application process. There are a small number of records listed as ‘unknown’, mainly in postgraduate borrower records, which reflect legacy data quality issues in this field in older loan records

The reasons for cancelled or written-off loans include statutory cancellations and write-offs (including those arising from the age of the borrower and eligible Access to Higher Education loan write-offs), death of the borrower, disability, trivial balances and losses through fraud (including phishing).

Question to the Department for Education:

To ask the Secretary of State for Education, how many EU national student loan borrowers living abroad have made no loan repayments in the past 12 months.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

There are 103,400 EU borrowers living overseas who have a loan which has become eligible for repayment. Of these, 43,700 are earning above the repayment threshold or have unknown earnings but have made no loan repayments in the last 12 months.

An EU borrower is a borrower who was originally domiciled in an EU country prior to entering higher education in England. Tuition fee funding for new EU students in England without ‘settled’ or ‘pre-settled’ status’ ceased in the 2021/2022 academic year. However, those continuing a course remain eligible for financial support for the duration of their course, in addition to those covered by the Withdrawal Agreements, subject to meeting other residency and course requirements.

The government is resolute in our commitment to protecting public money in higher education and we are taking firm action to address serious concerns about the exploitation of the student funding system.

If borrowers based overseas fail to remain in contact with the Student Loans Company (SLC), they are placed in arrears by SLC applying a default required repayment rate, and the outstanding balance can be pursued as debt.

The public expects these debts to be paid and so do we. That is why we are investing in the SLC’s ability to collect debt and working closely with them to go further on getting back what is owed.

Question to the Department for Education:

To ask the Secretary of State for Education, what guidance her Department provides to large employers launching work experience initiatives to ensure that placements are paired with formal qualifications or skills accreditation.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

T Levels are the flagship technical qualification for 16 to 19-year-olds and include a mandatory industry placement. These placements provide students with substantial, high-quality, hands‑on experience to develop the skills needed for future employment. Departmental guidance supports providers and employers to design placements with learning goals linked to curriculum content, enabling students to apply the skills and knowledge gained through their qualification. Guidance is available at:

https://www.gov.uk/government/publications/t-level-industry-placements-guidance-for-providers.

The department also provides a national programme of support to help employers deliver high-quality industry placements, including workshops, webinars and practical online guidance. Further details can be found at: https://employers.tlevels.gov.uk/hc/en-gb.

In addition, the government is introducing new technical educational routes from age 14. These new pathways will combine high-quality vocational qualifications alongside GCSEs, careers guidance and meaningful work experience opportunities. The department will work closely with the Careers & Enterprise Company to provide guidance for employers on offering high-quality work experience placements aligned with these pathways.

Question to the Department for Education:

To ask the Secretary of State for Education, how many of non-UK nationals received student finance in the 2024–25 academic year were qualified for support on the basis of holding pre-settled or settled status under the EU Settlement Scheme, broken down by (a) pre-settled status, (b) settled status and (c) EU family member status.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The department is not able to provide the requested data on pre-settled status, settled status and status related to an EU family member in the required timescale.

The Student Loans Company (SLC) holds data on the residency category under which the borrower is eligible for funding. However, these are not held in a format which can be readily and robustly reported in the requested breakdowns. The department and the SLC are undertaking work to improve the quality and consistency of data provided in this area. Once this work is complete, the department expects to be able to provide information in response to such questions in required timescales.

Question to the Department for Education:

To ask the Secretary of State for Education, with reference to Student Loans Company (SLC) data showing that non-UK nationals received approximately £4 billion in student finance in the 2024-2025 academic year, what proportion of higher education lending this amount represents.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The total value of student loans issued, by nationality of recipient, for academic years 2020/21 through to 2024/25 was published in response to Question 296 from the right hon. Member for Harborough, Oadby and Wigston.

In the 2024/25 academic year, non-UK nationals received £3.97 billion in student loans, representing 20.4% of the total loan value of student loans issued in that year.

Eligibility for student finance is determined by immigration status and residency, rather than nationality alone, ensuring that access to support reflects an individual’s established connection to the UK. To be eligible, a student must ordinarily be a resident in England and be settled or have a recognised connection with the UK. Students must also have been ordinarily a resident in the UK, the Channel Islands, the Isle of Man and/or a British Overseas Territory for the 3 years prior to the first day of the first academic year of their course. Some individuals are exempt from these requirements. For example, those granted refugee status are not required to meet the standard settlement and residency criteria.

Question to the Department for Education:

To ask the Secretary of State for Education, what steps her Department is taking to ensure young people in Leicester East have access to education and training opportunities.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The government is increasing funding per student in 16 to 19 education and making funding available as the number of young people increases. As a result, total 16 to 19 funding will increase from £7.6 billion in the 2024/25 academic year to over £9 billion in 2026/27.

In addition, for the 2026/27 academic year, we are committing to fund all exceptional in-year growth in 16 to 19 funded students. This means that institutions can have confidence to offer suitable places in post-16 education for every young person that wants one. Leicester College and Wyggeston and Queen Elizabeth I College have also benefited from funding awards through the recent Post-16 and Construction Skills Capacity funding round.

Question to the Department for Education:

To ask the Secretary of State for Education, what steps her Department takes to verify the continuous UK residence requirements for late EU Settlement Scheme applicants before student finance eligibility is granted.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

Student Finance England (SFE) is responsible for assessing personal and course eligibility for higher education student support. To be eligible for student finance an applicant must satisfy the criteria within the Education (Student Support) Regulations 2011 (as amended).

Where a late applicant to the EU Settlement Scheme is required to demonstrate that they meet the relevant residence requirements for student support, SFE considers information provided by the applicant about their residence history and may request supporting evidence, such as employment records, tenancy agreements, utility bills or other documentation where necessary to establish eligibility. The Home Office remains responsible for determining an individual's immigration status.

A Certificate of Application does not, by itself, confer entitlement to student support.

In assessing eligibility, SFE may require applicants to provide information and evidence relating to their residence history to determine whether they satisfy the relevant residence requirements set out in the student support regulations.

Additionally, SLC rely on accurate information provided by the Home Office regarding an applicant’s immigration status as the Home Office is the competent authority on such matters.

Question to the Department for Education:

To ask the Secretary of State for Education, what assessment her Department has made of the adequacy of Student Loans Company figures on the number of Romanian nationals who received in student loans in 2024-2025.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The department recently published data on Romanian nationals who received student loans in 2024/25, in the response to Question 10803 to the hon. Member for Harborough, Oadby and Wigston.

These figures reflect recent work by the department and the Student Loans Company (SLC) to strengthen data quality and consistency. The department and the SLC now hold robust information on current borrowers’ UK national status and nationality.

This process has reduced the number of ‘unknown’ records of student loan recipients by nationality to less than 0.07% in 2024/25 academic year. This is a live management information dataset which is not static, and data can be updated over time as SLC update their records and re-categorise data.

Responses to previous parliamentary questions used nationality as self‑reported by applicants on their Student Finance application form. Under that approach, UK nationals could record an additional nationality alongside proof of their UK national status, which led to inconsistent reporting for borrowers who held UK national status.

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, what steps HM Treasury is taking to support private-sector investment in productivity sectors and critical infrastructure in Leicester East.

Answered by Emma Reynolds - Chief Secretary to the Treasury

The Government's ambition is to support good growth across all parts of the United Kingdom. As set out in the Prime Minister's recent Machinery of Government Statement, No10 North will be responsible for driving good growth through devolution and working in close partnership with local leaders, businesses, and communities to strengthen place-based growth

We are also committed to fundamentally rewiring the way our country works, transferring greater powers, funding and accountability to the local leaders who know what it takes to drive growth and attract investment in their areas

As part of this we have provided support to Leicester through the Pride in Place fund, allowing neighbourhoods like Eyres Monsell, Braunstone Park West and Thurnby Lodge to decide where this is best spent, with each receiving £20m

This government has already taken first steps to tackle some of the barriers to private sector investment, including driving planning reform, removing the ban on the development of onshore wind farms, and expanding the Office for Investment. Regions across the UK benefit from British Business Bank's Nation and Regions Investment Funds, including the £400m Midlands Engine Investment Fund, which is still deploying capital.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to protect NHS emergency care staff from violence and aggression from patients and the public.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

I refer the Hon. Member to the answers provided on 15 September in response to Questions 27894 and 27895 and on 19 June in response to Question 3468.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on the proportion of patients aged 18 to 25 in England prescribed a selective serotonin reuptake inhibitor who received a follow-up review within one week, in line with NICE guideline NG222.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has taken forward the recommendations of the Commission on Human Medicines. The timetable for the revised patient information leaflet (PIL) is for it to be available electronically from October and for hard copy availability within packs of medicines three to six months later. The patient card will also be available electronically from October and will begin to be available in or on the box of antidepressant medicine within three to six months.

As an interim measure, the MHRA is working with the manufacturers’ trade associations to evaluate the feasibility of earlier access to the hard copy of the card for patients via pharmacies. The ancillary leaflet is being developed with other healthcare system partners and should be available early in 2027.

The MHRA has requested updates to the PILs for all antidepressants involved in the review to be submitted for approval. The PIL updates require review by the MHRA to ensure accuracy of messaging, and it is the aim for electronic versions of the PILs to be made available as soon as practicable in October.

The MHRA logs all Prevention of Future Deaths reports it receives and can confirm that since 2020, four reports concerning the prescribing of antidepressants, or their safety information have been sent to the MHRA. Responses have been issued in each case. The MHRA sought the advice of several independent committees on the reports and the potential need for regulatory action. In response to some of these reports and the feedback from families and patients, the MHRA convened the Expert Working Group on antidepressant risk minimisation, which made several recommendations for the MHRA and wider healthcare system, including updates to clinical guidance and regulatory documents.

The independent Expert Working Group on antidepressant risk minimisation considered all regulatory options for improving awareness of the risk of suicidal thoughts and behaviours, including adding a warning on the box, in addition to updates to the PILs. For many antidepressant medicines, the inclusion of additional information beyond the statutory requirements is limited by space available on the box. The patient card will be available on or in the box and will be detachable and easily portable, and will provide context to safety messaging and signpost patients on where to get help.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what comparative assessment she has made of the effectiveness of (a) on-pack warnings and (b) patient information leaflets in communicating the risk of suicidal behaviour associated with antidepressant medicines; and whether the Commission on Human Medicines Expert Working Group considered on-pack warnings as part of its review.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has taken forward the recommendations of the Commission on Human Medicines. The timetable for the revised patient information leaflet (PIL) is for it to be available electronically from October and for hard copy availability within packs of medicines three to six months later. The patient card will also be available electronically from October and will begin to be available in or on the box of antidepressant medicine within three to six months.

As an interim measure, the MHRA is working with the manufacturers’ trade associations to evaluate the feasibility of earlier access to the hard copy of the card for patients via pharmacies. The ancillary leaflet is being developed with other healthcare system partners and should be available early in 2027.

The MHRA has requested updates to the PILs for all antidepressants involved in the review to be submitted for approval. The PIL updates require review by the MHRA to ensure accuracy of messaging, and it is the aim for electronic versions of the PILs to be made available as soon as practicable in October.

The MHRA logs all Prevention of Future Deaths reports it receives and can confirm that since 2020, four reports concerning the prescribing of antidepressants, or their safety information have been sent to the MHRA. Responses have been issued in each case. The MHRA sought the advice of several independent committees on the reports and the potential need for regulatory action. In response to some of these reports and the feedback from families and patients, the MHRA convened the Expert Working Group on antidepressant risk minimisation, which made several recommendations for the MHRA and wider healthcare system, including updates to clinical guidance and regulatory documents.

The independent Expert Working Group on antidepressant risk minimisation considered all regulatory options for improving awareness of the risk of suicidal thoughts and behaviours, including adding a warning on the box, in addition to updates to the PILs. For many antidepressant medicines, the inclusion of additional information beyond the statutory requirements is limited by space available on the box. The patient card will be available on or in the box and will be detachable and easily portable, and will provide context to safety messaging and signpost patients on where to get help.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on how many Prevention of Future Deaths reports concerning the prescribing of, or safety information for, antidepressant medicines the Medicines and Healthcare products Regulatory Agency has received since 2020; and in how many cases guidance or product information was subsequently amended.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has taken forward the recommendations of the Commission on Human Medicines. The timetable for the revised patient information leaflet (PIL) is for it to be available electronically from October and for hard copy availability within packs of medicines three to six months later. The patient card will also be available electronically from October and will begin to be available in or on the box of antidepressant medicine within three to six months.

As an interim measure, the MHRA is working with the manufacturers’ trade associations to evaluate the feasibility of earlier access to the hard copy of the card for patients via pharmacies. The ancillary leaflet is being developed with other healthcare system partners and should be available early in 2027.

The MHRA has requested updates to the PILs for all antidepressants involved in the review to be submitted for approval. The PIL updates require review by the MHRA to ensure accuracy of messaging, and it is the aim for electronic versions of the PILs to be made available as soon as practicable in October.

The MHRA logs all Prevention of Future Deaths reports it receives and can confirm that since 2020, four reports concerning the prescribing of antidepressants, or their safety information have been sent to the MHRA. Responses have been issued in each case. The MHRA sought the advice of several independent committees on the reports and the potential need for regulatory action. In response to some of these reports and the feedback from families and patients, the MHRA convened the Expert Working Group on antidepressant risk minimisation, which made several recommendations for the MHRA and wider healthcare system, including updates to clinical guidance and regulatory documents.

The independent Expert Working Group on antidepressant risk minimisation considered all regulatory options for improving awareness of the risk of suicidal thoughts and behaviours, including adding a warning on the box, in addition to updates to the PILs. For many antidepressant medicines, the inclusion of additional information beyond the statutory requirements is limited by space available on the box. The patient card will be available on or in the box and will be detachable and easily portable, and will provide context to safety messaging and signpost patients on where to get help.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that revised patient information leaflet wording on the risk of suicidal behaviour is implemented simultaneously across all 28 antidepressant medicines included in the Commission on Human Medicines review, rather than as each marketing authorisation holder updates its product information.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has taken forward the recommendations of the Commission on Human Medicines. The timetable for the revised patient information leaflet (PIL) is for it to be available electronically from October and for hard copy availability within packs of medicines three to six months later. The patient card will also be available electronically from October and will begin to be available in or on the box of antidepressant medicine within three to six months.

As an interim measure, the MHRA is working with the manufacturers’ trade associations to evaluate the feasibility of earlier access to the hard copy of the card for patients via pharmacies. The ancillary leaflet is being developed with other healthcare system partners and should be available early in 2027.

The MHRA has requested updates to the PILs for all antidepressants involved in the review to be submitted for approval. The PIL updates require review by the MHRA to ensure accuracy of messaging, and it is the aim for electronic versions of the PILs to be made available as soon as practicable in October.

The MHRA logs all Prevention of Future Deaths reports it receives and can confirm that since 2020, four reports concerning the prescribing of antidepressants, or their safety information have been sent to the MHRA. Responses have been issued in each case. The MHRA sought the advice of several independent committees on the reports and the potential need for regulatory action. In response to some of these reports and the feedback from families and patients, the MHRA convened the Expert Working Group on antidepressant risk minimisation, which made several recommendations for the MHRA and wider healthcare system, including updates to clinical guidance and regulatory documents.

The independent Expert Working Group on antidepressant risk minimisation considered all regulatory options for improving awareness of the risk of suicidal thoughts and behaviours, including adding a warning on the box, in addition to updates to the PILs. For many antidepressant medicines, the inclusion of additional information beyond the statutory requirements is limited by space available on the box. The patient card will be available on or in the box and will be detachable and easily portable, and will provide context to safety messaging and signpost patients on where to get help.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the statement by the Medicines and Healthcare products Regulatory Agency of 1 December 2025 on the conclusions of the Commission on Human Medicines Expert Working Group on antidepressants, what the expected timetable is for (a) the revised patient information leaflet wording, (b) the patient card and (c) the ancillary leaflet to be made available to patients.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has taken forward the recommendations of the Commission on Human Medicines. The timetable for the revised patient information leaflet (PIL) is for it to be available electronically from October and for hard copy availability within packs of medicines three to six months later. The patient card will also be available electronically from October and will begin to be available in or on the box of antidepressant medicine within three to six months.

As an interim measure, the MHRA is working with the manufacturers’ trade associations to evaluate the feasibility of earlier access to the hard copy of the card for patients via pharmacies. The ancillary leaflet is being developed with other healthcare system partners and should be available early in 2027.

The MHRA has requested updates to the PILs for all antidepressants involved in the review to be submitted for approval. The PIL updates require review by the MHRA to ensure accuracy of messaging, and it is the aim for electronic versions of the PILs to be made available as soon as practicable in October.

The MHRA logs all Prevention of Future Deaths reports it receives and can confirm that since 2020, four reports concerning the prescribing of antidepressants, or their safety information have been sent to the MHRA. Responses have been issued in each case. The MHRA sought the advice of several independent committees on the reports and the potential need for regulatory action. In response to some of these reports and the feedback from families and patients, the MHRA convened the Expert Working Group on antidepressant risk minimisation, which made several recommendations for the MHRA and wider healthcare system, including updates to clinical guidance and regulatory documents.

The independent Expert Working Group on antidepressant risk minimisation considered all regulatory options for improving awareness of the risk of suicidal thoughts and behaviours, including adding a warning on the box, in addition to updates to the PILs. For many antidepressant medicines, the inclusion of additional information beyond the statutory requirements is limited by space available on the box. The patient card will be available on or in the box and will be detachable and easily portable, and will provide context to safety messaging and signpost patients on where to get help.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the Royal College of Emergency Medicine survey data published in its Safe to Care campaign report, 7 September 2026, what steps her Department is taking to reduce hospital overcrowding and corridor care to help prevent staff abuse.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

I refer the Hon. Member to the answer I gave on 16 July to Question 17438, which sets out the Government’s approach to reducing pressures across urgent and emergency care, including overcrowding and corridor care. NHS England also provides targeted support to trusts experiencing the highest levels of corridor care, including patient flow and reducing overcrowding.

The NHS Staff Standards introduced in July 2026 include a specific standard on violence prevention and reduction. This requires National Health Service organisations to take action to prevent and reduce violence and abuse towards staff, including through risk assessment, training, reporting arrangements, and support for staff following incidents.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential implications for her Department's policies on NHS staff retention of findings by the Royal College of Emergency Medicine in its report entitled Safe to Care, published on 7 September 2026, showing that 73 per cent of A&E staff experience or witness violence or aggression on a daily or weekly basis.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

I refer the Hon. Member to the answers provided on 15 September in response to Questions 27894 and 27895 and on 19 June in response to Question 3468.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help tackle discrimination against emergency care workers.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

I refer the Hon. Member to the answers provided on 15 September in response to Questions 27894 and 27895 and on 19 June in response to Question 3468.

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, what assessment he has made of the potential implications for his policies of the estimate in the September 2026 Oxford Economics report, titled The UK’s Investment Shortfall, of the potential impact of closing the UK’s business investment gap with G7 nations on household disposable income.

Answered by Torsten Bell - Parliamentary Secretary (HM Treasury)

Raising investment is critical to raising living standards, as Oxford Economics’ report lays out. That is why increasing investment is central to the Government’s approach to growth, as outlined by the Chancellor on 7 September. The government is taking action to mobilise public and private capital – including through its Public Financial Institutions, such as the National Wealth Fund and British Business Bank, which are attracting more private investment into growth-enhancing projects. Investment has grown strongly since the start of this parliament, rising by 6.9%, driven by robust government and business investment.

This stronger growth is already benefiting households. Real household disposable income has increased by 1.1% since the start of this Parliament, after falling by 2.3% in the previous Parliament. This has left the average person's real disposable income around £600 higher in the past year than the final year of the previous Parliament.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the Government is planning changes to policy to help ensure that women are not coerced or unduly pressured into becoming surrogates.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

The Government supports surrogacy as a part of assisted conception options and recognises the important part it can play in supporting people seeking to start a family.

The Department has published guidance on the care of surrogates and intended parents in surrogate births, which is available at the following link:

https://www.gov.uk/government/publications/having-a-child-through-surrogacy/care-in-surrogacy-guidance-for-the-care-of-surrogates-and-intended-parents-in-surrogate-births-in-england-and-wales

Question to the Department for Transport:

To ask the Secretary of State for Transport, pursuant to the Answer of 13 July 2026 to Question 16605 on Parking Offences: Bournemouth, Christchurch and Poole, whether her Department plans to (a) conduct further pilots and trials and (b) amend legislation on municipal parking fines in England outside London.

Answered by Justin Madders - Parliamentary Under-Secretary (Department for Transport)

The Department is not conducting trials. The BCP trial was conducted by BCP. There are no plans to amend legislation on municipal parking fines outside London.

National Cholesterol Month